Literature DB >> 8977001

The enhanced S cone syndrome: an analysis of receptoral and post-receptoral changes.

V C Greenstein1, Q Zaidi, D C Hood, B Spehar, A V Cideciyan, S G Jacobson.   

Abstract

The purpose of the study was to test the hypothesis that the retinae of patients with enhanced S cone syndrome (ESCS) have more S cones than the normal retina and these cones have replaced some of the L and M cones. Standard and spectral full-field electroretinograms, measurements of L, M, and S cone system sensitivities and S cone acuity were obtained from three patients with ESCS. The results were qualitatively consistent with the presence of more S cones and more S cone ganglion cells. To test this hypothesis further, a model of the receptoral and post-receptoral components of the S cone system was used in conjunction with psychophysical measurements of S cone system sensitivity under flashed and steady-state adaptation conditions. Within the context of the model, the data were consistent with an increase in the number of S cones and S - (L + M) ganglion cells and with a decrease in the total L + M cone input to each S - (L + M) ganglion cell.

Entities:  

Mesh:

Year:  1996        PMID: 8977001     DOI: 10.1016/0042-6989(96)00073-9

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  9 in total

1.  Electroretinographic evaluation of the retinal S-cone system.

Authors:  Maja Sustar; Marko Hawlina; Jelka Brecelj
Journal:  Doc Ophthalmol       Date:  2011-11-27       Impact factor: 2.379

2.  Electroretinography and optical coherence tomography reveal abnormal post-photoreceptoral activity and altered retinal lamination in patients with enhanced S-cone syndrome.

Authors:  M Sustar; D Perovšek; I Cima; B Stirn-Kranjc; M Hawlina; J Brecelj
Journal:  Doc Ophthalmol       Date:  2015-02-07       Impact factor: 2.379

3.  Two-color pupillometry in enhanced S-cone syndrome caused by NR2E3 mutations.

Authors:  Frederick T Collison; Jason C Park; Gerald A Fishman; Edwin M Stone; J Jason McAnany
Journal:  Doc Ophthalmol       Date:  2016-03-31       Impact factor: 2.379

4.  Enhanced S-cone syndrome with preserved macular structure and severely depressed retinal function.

Authors:  Ivan Cima; Jelka Brecelj; Maja Sustar; Frauke Coppieters; Bart P Leroy; Elfride De Baere; Marko Hawlina
Journal:  Doc Ophthalmol       Date:  2012-06-19       Impact factor: 2.379

5.  The nuclear receptor NR2E3 plays a role in human retinal photoreceptor differentiation and degeneration.

Authors:  Ann H Milam; Linda Rose; Artur V Cideciyan; Mark R Barakat; Wai-Xing Tang; Nisha Gupta; Tomas S Aleman; Alan F Wright; Edwin M Stone; Val C Sheffield; Samuel G Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

6.  New truncation mutation of the NR2E3 gene in a Japanese patient with enhanced S-cone syndrome.

Authors:  Kazuki Kuniyoshi; Takaaki Hayashi; Hiroyuki Sakuramoto; Hiroshi Mishima; Hiroshi Tsuneoka; Kazushige Tsunoda; Takeshi Iwata; Yoshikazu Shimomura
Journal:  Jpn J Ophthalmol       Date:  2016-08-13       Impact factor: 2.447

7.  Expanded clinical spectrum of enhanced S-cone syndrome.

Authors:  Suzanne Yzer; Irene Barbazetto; Rando Allikmets; Mary J van Schooneveld; Arthur Bergen; Stephen H Tsang; Samuel G Jacobson; Lawrence A Yannuzzi
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

8.  Rod photoreceptor differentiation in fetal and infant human retina.

Authors:  Anita Hendrickson; Keely Bumsted-O'Brien; Riccardo Natoli; Visvanathan Ramamurthy; Daniel Possin; Jan Provis
Journal:  Exp Eye Res       Date:  2008-08-20       Impact factor: 3.467

9.  Developing an Outcome Measure With High Luminance for Optogenetics Treatment of Severe Retinal Degenerations and for Gene Therapy of Cone Diseases.

Authors:  Artur V Cideciyan; Alejandro J Roman; Samuel G Jacobson; Boyuan Yan; Michele Pascolini; Jason Charng; Simone Pajaro; Sheila Nirenberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-06-01       Impact factor: 4.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.